

BACE2 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP6121a**Specification****BACE2 Antibody (Center) Blocking Peptide -
Product Information**Primary Accession [Q9Y5Z0](#)**BACE2 Antibody (Center) Blocking Peptide -
Additional Information****Gene ID** 25825**Other Names**

Beta-secretase 2, Aspartic-like protease 56 kDa, Aspartyl protease 1, ASP1, Asp 1, Beta-site amyloid precursor protein cleaving enzyme 2, Beta-site APP cleaving enzyme 2, Down region aspartic protease, DRAP, Memapsin-1, Membrane-associated aspartic protease 1, Theta-secretase, BACE2, AEPLC, ALP56, ASP21

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6121a](#) was selected from the Center region of human BACE2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**BACE2 Antibody (Center) Blocking Peptide -
Background**

Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease and a frequent complication of Down syndrome. Amyloid beta peptide is generated by proteolytic cleavage of amyloid precursor protein by 2 proteases, one of which is the protein encoded by BACE2. This gene localizes to the 'Down critical region' of chromosome 21. The encoded protein, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease.

**BACE2 Antibody (Center) Blocking Peptide -
References**

Clark, H.F., et al., Genome Res. 13(10):2265-2270 (2003).Basi, G., et al., J. Biol. Chem. 278(34):31512-31520 (2003).Barbiero, L., et al., Exp. Neurol. 182(2):335-345 (2003).Shi, X.P., et al., J. Biol. Chem. 278(23):21286-21294 (2003).Kondoh, K., et al., Breast Cancer Res. Treat. 78(1):37-44 (2003).

**BACE2 Antibody (Center) Blocking Peptide -
Protein Information****Name** BACE2**Synonyms** AEPLC, ALP56, ASP21**Function**

Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves APP, between residues 690 and 691, leading to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. It has also been shown that it can cleave APP between residues 671 and 672. Responsible also for the proteolytic processing of CLTRN in pancreatic beta cells (PubMed:21907142).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Golgi apparatus. Endoplasmic reticulum. Endosome

Tissue Location

Brain. Present in neurons within the hippocampus, frontal cortex and temporal cortex (at protein level). Expressed at low levels in most peripheral tissues and at higher levels in colon, kidney, pancreas, placenta, prostate, stomach and trachea. Expressed at low levels in the brain. Found in spinal cord, medulla oblongata, substantia nigra and locus coeruleus. Expressed in the ductal epithelium of both normal and malignant prostate.

**BACE2 Antibody (Center) Blocking Peptide
- Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)